Apr182024Uncategorized Category: UncategorizedBy Charlotte Maddalena18 April 2024 Author: Charlotte Maddalena Post navigationPreviousPrevious post:Six new projects supported by our FoundationNextNext post:ORPHELIA Pharma and University of Birmingham strengthen their collaboration to support the registration of KIZFIZO®Related PostsORPHELIA Pharma collaborates with Oscar Lambret clinical center11 June 2024ORPHELIA Pharma recrute un/une Chef de Projet Réglementaire Senior7 June 2024ORPHELIA Pharma and University of Birmingham strengthen their collaboration to support the registration of KIZFIZO®22 May 2024Six new projects supported by our Foundation18 March 2024Four houses for the FAOMA call for projects18 March 2024ORPHELIA Pharma announces the publication of two scientific articles on KIZFIZO, the first pediatric drinkable formulation of temozolomide for the treatment of refractory or relapsed neuroblastoma9 January 2024
ORPHELIA Pharma and University of Birmingham strengthen their collaboration to support the registration of KIZFIZO®22 May 2024
ORPHELIA Pharma announces the publication of two scientific articles on KIZFIZO, the first pediatric drinkable formulation of temozolomide for the treatment of refractory or relapsed neuroblastoma9 January 2024
